Extracellular vesicles (EVs) can be functionalized to display specific protein receptors on their surface. However, surface-display technology typically labels only a small fraction of the EV population. Here, we show that the joint display of two different therapeutically relevant protein receptors on EVs can be optimized by systematically screening EV-loading protein moieties. We used cytokine-binding domains derived from tumour necrosis factor receptor 1 (TNFR1) and interleukin-6 signal transducer (IL-6ST), which can act as decoy receptors for the pro-inflammatory cytokines tumour necrosis factor alpha (TNF-α) and IL-6, respectively. We found that the genetic engineering of EV-producing cells to express oligomerized exosomal sorting domains and the N-terminal fragment of syntenin (a cytosolic adaptor of the single transmembrane domain protein syndecan) increased the display efficiency and inhibitory activity of TNFR1 and IL-6ST and facilitated their joint display on EVs. In mouse models of systemic inflammation, neuroinflammation and intestinal inflammation, EVs displaying the cytokine decoys ameliorated the disease phenotypes with higher efficacy as compared with clinically approved biopharmaceutical agents targeting the TNF-α and IL-6 pathways.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Stem Cell Research & Therapy Open Access 15 August 2023
Nature Communications Open Access 07 August 2023
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$99.00 per year
only $8.25 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
The main data supporting the results in this study are available within the paper and its Supplementary Information. The raw and analysed datasets are available at Figshare (https://figshare.com/projects/Raw_and_Analysed_data_Gupta_et_al_NBME_2021/119859).
Armstrong, J. P. K., Holme, M. N. & Stevens, M. M. Re-engineering extracellular vesicles as smart nanoscale therapeutics. ACS Nano 11, 69–83 (2017).
Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 29, 341–345 (2011).
El-Andaloussi, S. et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 7, 2112–2126 (2012).
Wiklander, O. P. B. et al. Extracellular vesicle in vivo biodistribution is determined by cell source, route of administration and targeting. J. Extracell. Vesicles https://doi.org/10.3402/jev.v4.26316 (2015).
Cooper, J. M. et al. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord. 29, 1476–1485 (2014).
Jeppesen, D. K. et al. Reassessment of exosome composition. Cell 177, 428–445 (2019).
Willms, E. et al. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci. Rep. 6, 22519 (2016).
Vagner, T. et al. Protein composition reflects extracellular vesicle heterogeneity. Proteomics 19, 1800167 (2019).
Crescitelli, R. et al. Subpopulations of extracellular vesicles from human metastatic melanoma tissue identified by quantitative proteomics after optimized isolation. J. Extracell. Vesicles 9, 1722433 (2020).
Kim, E. Y. & Moudgil, K. D. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. Cytokine 98, 87–96 (2017).
Moudgil, K. D. & Choubey, D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J. Interferon Cytokine Res. 31, 695–703 (2011).
Garbers, C., Heink, S., Korn, T. & Rose-John, S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat. Rev. Drug Discov. 17, 395–412 (2018).
Kalliolias, G. D. & Ivashkiv, L. B. TNF biology, pathogenic mechanisms and emerging therapeutic strategies. Nat. Rev. Rheumatol. 12, 49–62 (2016).
Sedger, L. M. & McDermott, M. F. TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants – past, present and future. Cytokine Growth Factor Rev. 25, 453–472 (2014).
Wolf, J., Rose-John, S. & Garbers, C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 70, 11–20 (2014).
Simpson, R. J., Kalra, H. & Mathivanan, S. Exocarta as a resource for exosomal research. J. Extracell. Vesicles 1, 18374 (2012).
Hurwitz, S. N. et al. Proteomic profiling of NCI-60 extracellular vesicles uncovers common protein cargo and cancer type-specific biomarkers. Oncotarget 7, 86999–87015 (2016).
Sork, H. et al. Heterogeneity and interplay of the extracellular vesicle small RNA transcriptome and proteome. Sci. Rep. 8, 10813 (2018).
Xanthoulea, S. et al. Tumor necrosis factor (TNF) receptor shedding controls thresholds of innate immune activation that balance opposing TNF functions in infectious and inflammatory diseases. J. Exp. Med. 200, 367–376 (2004).
Meier, S., Güthe, S., Kiefhaber, T. & Grzesiek, S. Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable β-hairpin: atomic details of trimer dissociation and local β-hairpin stability from residual dipolar couplings. J. Mol. Biol. 344, 1051–1069 (2004).
Ellenberger, T. E., Brandl, C. J., Struhl, K. & Harrison, S. C. The GCN4 basic region leucine zipper binds DNA as a dimer of uninterrupted α helices: crystal structure of the protein-DNA complex. Cell 71, 1223–1237 (1992).
Jensen, M. R. et al. Structural description of the nipah virus phosphoprotein and its interaction with stat1. Biophys. J. https://doi.org/10.1016/j.bpj.2020.04.010 (2020).
Sliepen, K., van Montfort, T., Melchers, M., Isik, G. & Sanders, R. W. Immunosilencing a highly immunogenic protein trimerization domain. J. Biol. Chem. 290, 7436–7442 (2015).
Dooley, K. et al. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties. Mol. Ther. 29, 1729–1743 (2021).
Théry, C. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750 (2018).
Wiklander, O. P. B. et al. Systematic methodological evaluation of a multiplex bead-based flow cytometry assay for detection of extracellular vesicle surface signatures. Front. Immunol. 9, 1326 (2018).
Pelosi, L. et al. Increased levels of interleukin-6 exacerbate the dystrophic phenotype in mdx mice. Hum. Mol. Genet. 24, 6041–6053 (2015).
Saleh, A. F. et al. Extracellular vesicles induce minimal hepatotoxicity and immunogenicity. Nanoscale 11, 6990–7001 (2019).
Zhu, X. et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J. Extracell. Vesicles 6, 1324730 (2017).
Sejwal, K. et al. Proteoliposomes—a system to study membrane proteins under buffer gradients by cryo-EM. Nanotechnol. Rev. 6, 57–74 (2017).
Gupta, D. et al. Quantification of extracellular vesicles in vitro and in vivo using sensitive bioluminescence imaging. J. Extracell. Vesicles 9, 1800222 (2020).
Desmet, J. et al. Structural basis of IL-23 antagonism by an Alphabody protein scaffold. Nat. Commun. 5, 5237 (2014).
Göbel, K., Ruck, T. & Meuth, S. G. Cytokine signaling in multiple sclerosis: lost in translation. Mult. Scler. 24, 432–439 (2018).
Görgens, A. et al. Optimisation of imaging flow cytometry for the analysis of single extracellular vesicles by using fluorescence-tagged vesicles as biological reference material. J. Extracell. Vesicles 8, 1587567 (2019).
Reshke, R. et al. Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-019-0502-4 (2020).
Kamerkar, S. et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature 546, 498–503 (2017).
Corso, G. et al. Systematic characterization of extracellular vesicle sorting domains and quantification at the single molecule—single vesicle level by fluorescence correlation spectroscopy and single particle imaging. J. Extracell. Vesicles 8, 1663043 (2019).
Gao, X. et al. Anchor peptide captures, targets, and loads exosomes of diverse origins for diagnostics and therapy. Sci. Transl. Med. 10, eaat0195 (2018).
Wiklander, O. P. B., Brennan, M., Lötvall, J., Breakefield, X. O. & Andaloussi, S. E. L. Advances in therapeutic applications of extracellular vesicles. Sci. Transl. Med. 11, 8521 (2019).
Rayamajhi, S. & Aryal, S. Surface functionalization strategies of extracellular vesicles. J. Mater. Chem. B 8, 4552–4569 (2020).
Baietti, M. F. et al. Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol. 14, 677–685 (2012).
Fang, Y. et al. Higher-order oligomerization targets plasma membrane proteins and HIV Gag to exosomes. PLoS Biol. 5, e158 (2007).
Conceição, M. et al. Engineered extracellular vesicle decoy receptor-mediated modulation of the IL6 trans-signalling pathway in muscle. Biomaterials 266, 120435 (2021).
Lai, C. P. et al. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano 8, 483–494 (2014).
Perets, N. et al. Golden exosomes selectively target brain pathologies in neurodegenerative and neurodevelopmental disorders. Nano Lett. 19, 3422–3431 (2019).
Keller, M. D. et al. Decoy exosomes provide protection against bacterial toxins. Nature 579, 260–264 (2020).
de Carvalho, J. V. et al. Nef neutralizes the ability of exosomes from CD4+ T cells to act as decoys during HIV-1 infection. PLoS ONE 9, e113691 (2014).
Corso, G. et al. Reproducible and scalable purification of extracellular vesicles using combined bind-elute and size exclusion chromatography. Sci. Rep. 7, 11561 (2017).
Tertel, T. et al. High-resolution imaging flow cytometry reveals impact of incubation temperature on labelling of extracellular vesicles with antibodies. Cytometry A 97, 602–609 (2020).
Brkic, M. et al. Amyloid β oligomers disrupt blood–CSF barrier integrity by activating matrix metalloproteinases. J. Neurosci. 35, 12766–12778 (2015).
Raduolovic, K., Mak’Anyengo, R., Kaya, B., Steinert, A. & Niess, J. H. Injections of lipopolysaccharide into mice to mimic entrance of microbial-derived products after intestinal barrier breach. J. Vis. Exp. https://doi.org/10.3791/57610 (2018).
Scheiffele, F. & Fuss, I. J. Induction of TNBS colitis in mice. Curr. Protoc. Immunol. https://doi.org/10.1002/0471142735.im1519s49 (2002).
We acknowledge B. Vanneste and G. Van Imschoot for their assistance. A.G. is an International Society for Advancement of Cytometry Marylou Ingram Scholar 2019–2023. S.E.-A. is supported by H2020 EXPERT, the Swedish foundation of Strategic Research (SSF-IRC; FormulaEx), ERC CoG (DELIVER) and the Swedish Medical Research Council.
M.J.A.W. and S.E.-A. are founders of and consultants for Evox Therapeutics. D.G., O.P.B.W., A.G. and J.Z.N. are consultants for Evox Therapeutics. D.G., O.P.B.W., A.G., J.Z.N., M.J.A.W., P.L., A.d.F. and S.E.-A. have stock interest in Evox Therapeutics. J.H., P.L. and A.d.F. are employees of Evox Therapeutics. The other authors declare no competing interests.
Peer review information Nature Biomedical Engineering thanks Ke Cheng, Gregor Fuhrmann and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
A) Schematic illustration showing the generation of engineered decoy EVs at the cellular level. Producer cells are genetically modified to express cytokine receptors without the signalling domain fused to an EV sorting domain for efficient display of cytokine receptors on the surface of the secreted EVs (decoy EVs), which can decoy cytokines specifically. B-C) Mode size determined by NTA of indicated engineered HEK293T EVs purified from cells transfected with various B) TNFR1 display constructs and C) IL6ST display constructs. Central Value: Mean, Error bars: S.D (Technical replicate, n=5). D) Fold change in signal over untreated HEK293T NF-κB reporter cells, upon incubation of different doses of TNFα for 4 hours. Central Value: Mean, Error bars: S.D (Biological replicate, n = 3). E) Fold change in signal over untreated HEK293T STAT3 reporter cells, upon incubation of different doses of IL-6/sIL-6R for 12 hours. Central Value: Mean, Error bars: S.D (Biological replicate, n = 3).
Relative mRNA expression of pro inflammatory cytokines determined by qPCR (A) TNFα, (B) IL-6 in the spinal cord at day 16 in mice induced with EAE using MOG35-55 peptide and treated with S.C administration of either 4×1010 MSC TNFR1∆∆-FDN-NST EVs (n = 5) or MSC Ctrl EVs (n = 5) or Saline (n = 5) (On day 7, 10 & 13). For the same dataset as shown in Fig. 5b,c. Central Value: Mean, Error bars: S.D, Statistical significance calculated by one-way ANOVA compared with response of Saline treated animal. C) Relative change in clinical score of disease progression between day 16 and 13 in mice induced with EAE using MOG35-55 peptide and treated with I.V administration of either 1×1010 HEK293T IL-23B-LZ-NST EVs pre symptomatic (On day 5, 7 & 10) or 6×1010 HEK293T IL-23B-LZ-NST EVs post symptomatic (On day 13) or Saline. For the same dataset as shown in Fig. 5h, i. Central Value: Mean, Error bars: S.D, Statistical significance calculated by two-way ANOVA with Dunnett’s post-test compared with response of Saline treated animal.
Extended Data Fig. 3 The surface proteome is unaltered by the dual functionalization of engineered EVs.
A) Imaging flow cytometry analysis (IFCM) with dot plots and example event images in the double positive (DP) gate of MSC TNFR1∆∆-FDN-NST and MSC double decoy EVs stained with mIL6ST APC conjugated and hTNFR1 PE conjugated antibody. PBS + antibodies were used for background adjustment and for determining the gating strategy. B) Multiplex EV surface characterization of PAN (CD63, CD81, and CD9) positive, hTNFR1 positive and mIL6ST positive population in MSC double decoy EVs and MSC Ctrl EVs. Data represented as background corrected median APC fluorescence intensity determined by flow cytometry of EVs bound different capture beads and upon using APC labelled detection antibody. Central Value: Mean, Error bars: S.D, (Technical replicate, n = 5000-15000).
A) Increment in EV accumulation in various tissues in animal induced with IBD over healthy animal. B) Change in body weight 24 hours after treatment with different groups in mice induced with TNBS colitis. For the same data set as shown in Fig. 6g, h. C) Survival curve and D) percent change in relative bodyweight to initial weight over the disease course in mice induced with colitis by intrarectal injection of TNBS and treated with I.V administration (at 24 hours post disease induction) of either 3×1011 MSC double decoy EVs (n = 8) or PBS (n = 9).
About this article
Cite this article
Gupta, D., Wiklander, O.P.B., Görgens, A. et al. Amelioration of systemic inflammation via the display of two different decoy protein receptors on extracellular vesicles. Nat Biomed Eng 5, 1084–1098 (2021). https://doi.org/10.1038/s41551-021-00792-z
This article is cited by
Stem Cell Research & Therapy (2023)
Nature Communications (2023)
Nano Research (2023)
Nature Biotechnology (2022)